Merck still has a chance at being part of the Covid-19 treatment landscape.
The FDA is convening an advisory committee on Tuesday to consider the company’s antiviral pill, molnupiravir. But the discussion will highlight the drug’s limitations, including safety risks and limited efficacy, which could cut expectations for the drug’s long-term sales even more.
Analysts...
COVID-19 - Latest - Google News
November 30, 2021 at 05:49AM
https://ift.tt/3o4XsmD
Merck Shares Fall Ahead of FDA Panel Hearing on Covid Pill - Barron's
COVID-19 - Latest - Google News
https://ift.tt/2VQ2gy8
No comments:
Post a Comment